These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10739683)

  • 1. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
    Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients.
    Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Romanini C
    Gynecol Oncol; 1996 Apr; 61(1):16-21. PubMed ID: 8626110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment assessment of prognostic indicators in endometrial cancer.
    Mariani A; Sebo TJ; Katzmann JA; Keeney GL; Roche PC; Lesnick TG; Podratz KC
    Am J Obstet Gynecol; 2000 Jun; 182(6):1535-44. PubMed ID: 10871476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma.
    Pfisterer J; Kommoss F; Sauerbrei W; Rendl I; Kiechle M; Kleine W; Pfleiderer A
    Gynecol Oncol; 1995 Aug; 58(2):149-56. PubMed ID: 7622098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.
    Hamel NW; Sebo TJ; Wilson TO; Keeney GL; Roche PC; Suman VJ; Hu TC; Podratz KC
    Gynecol Oncol; 1996 Aug; 62(2):192-8. PubMed ID: 8751548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
    Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB; Iversen OE; Akslen LA
    Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
    Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
    Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial cancer: can nodal status be predicted with curettage?
    Mariani A; Sebo TJ; Katzmann JA; Roche PC; Keeney GL; Lesnick TG; Podratz KC
    Gynecol Oncol; 2005 Mar; 96(3):594-600. PubMed ID: 15721399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF; Liu MQ; Zhao Q
    Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
    Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
    Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.